Klinik und Poliklinik für Urologie und Kinderurologie

2025

Einrichtungsstatistik
Forschungsprojekte21
Publikationen37
Vorträge
Promotionen4
Verschiedene wissenschaftliche Aktivitäten

Forschungsprojekte

Projektleiter: PD Dr. med. Maximilian Brandt, PD Dr. Rene Mager, Dr. Anita Thomas

A Phase III Randomized, Open-Label, Multicenter Study to Determine the Efficacy and Safety of Durvalumab in Combination With Tremelimumab and Enfortumab Vedotin or Durvalumab in Combination With Enfortumab Vedotin for Perioperative Treatment in Patients Ineligible for Cisplatin or Who Refuse Cisplatin Undergoing Radical Cystectomy for Muscle InvasiveBladder Cancer (VOLGA)

Compare efficacy of durvalumab + tremelimumab + EV relative to cystectomy on pCR rate and EFS Compare the efficacy of durvalumab + EV relative to cystectomy on pCR rate, EFS, OS, EFS24, OS5, DFS, pDS rate, DSS, and metastasis-free survival (MFS) Compare the efficacy of durvalumab + tremelimumab + EV relative to cystectomy on OS, EFS24, OS5, DFS, pDS rate, DSS, and MFS

Laufzeit: 2022-2026
Projektleiter: PD Dr. Maximilian Brandt, Dr. Anita Thomas

ARTEMIS STUDYProspective, Multi-country, Comparative Observational Study (non-interventional) of clinical outcomes that benefit mHSPC patients treated with Apalutamide + ADT and Enzalutamide+ADT under routine clinical practice (ARTEMISpro)

Patients with metastatic hormone sensitive prostate cancer (mHSPC).

Laufzeit: 2023-2025
Projektleiter: Dr. Maximilian Brandt, Dr. Anita Thomas

BAY 88-8223 / 20510 RADIANT

A Phase 4, randomized, open-label, multicenter efficacy and safety study of standard dose of radium-223 dichloride vs. standard doses of novel anti-hormonal therapy (NAH) in patients with bone dominant metastatic castration resistant prostate cancer progressing on/after one line of NAH

Laufzeit: 2021-2025
Projektleiter: PD Dr. Maximilian Brandt, PD Dr. Rene Mager

BMS CA17-078: A Phase 3, Randomized, Study of Neoadjuvant Chemotherapy alone versus Neoadjuvant Chemotherapy plus Nivolumab or Nivolumab and BMS-986205, Followed by Continued Post-Surgery Therapy with Nivolumab or Nivolumab and BMS-986205 in Participants with Muscle Invasive Bladder Cancer

To compare the pCR rate of neoadjuvant nivolumab/BMS-986205 + GC  to neoadjuvante alone in all randomize participants.
To compare EFS of neoadjuvant nivolumab/BMS-986205 +
GC followed by continued nivolumab/BMS-986205 after
RC versus SOC GC followed by RC in all randomized
participants.

Sekundäre Endpunkte/Zielsetzungen:
To compare overall survival (OS) of neoadjuvant nivolumab/BMS-986205 + GC or nivolumab + GC followed by continued IO therapy after RC versus neoadjuvant SOC GC followed by RC in all randomized participants (Arm C vs Arm A and Arm B vs Arm A).
 
To describe the safety and tolerability of nivolumab and
nivolumab/BMS-986205 in combination with GC
chemotherapy.

Laufzeit: 2019-2025
Projektleiter: Dr. Dr. Gregor Duwe, PD Dr. Thomas Höfner, Univ.-Prof. Dr. Axel Haferkamp

KITTU - KI-unterstützte Therapiebegleitung am Beispiel der Urologie“/ AI-supported support in treatment recommendation for cancer patients in urology

In Western countries approximately every fourths new cancer diagnosis belongs to the urinary and genital organs. Recommending the best therapy is complex and has to take into account the individuality of each patients medical history as well as an extensive knowledge that can hardly be surveyed by individual experts. KITTU („KI-unterstützte Therapiebegleitung am Beispiel der Urologie“/ AI-supported support in treatment recommendation for cancer patients in urology) aims to develop an AI- system that supports the treatment of tumor patients in urology by demonstrating physicians and patients each therapeutic option available in their individual situation and supporting them in their decision-making process. KITTU thus contributes to relieving the burden on those involved in the process and to optimizing therapy decisions. With the help of KITTU we aim to increase evidence-based treatment recommendation in oncology in order to improve the quality of treatment and long-term survival of patients. Additionally, preventable side effects should be reduced while and overall quality of life will be improved. Once established in urology, the goal is to extend KITTU to other oncological diseases, thus enabling a significant improvement cancer care.

Laufzeit: 2022-2025
Projektleiter: Dr. Maximilian Haack, Univ.-Prof. Dr. Axel Haferkamp

Establishment of a microfluidic 3D cell culture model for simulating and inhibiting bone metastasis via antagonization of the CXCR4/CXCL12 signaling pathway in prostate cancer

Bone metastasis is a major driver of morbidity and mortality in advanced prostate cancer and is critically mediated by CXCR4/CXCL12 signaling. We develop a human microfluidic 3D bone cancer-on-chip model that recapitulates early metastatic seeding under physiologically relevant conditions. This platform enables functional validation of CXCR4 antagonists as anti-metastatic interventions. Our approach aims to accelerate translation of metastasis-preventive therapies into clinical application.

Laufzeit: 2025-2026
Projektleiter: Univ.-Prof. Dr. Axel Haferkamp, Elke Tafel-Stein

Prostate Cancer Outcome (PCO) Studie

In der PCO-Studie wird erstmalig die Lebensqualität von Patienten mit Prostatakarzinom mit einem weltweit einheitlichen Patientenfragebogen gemessen.

Laufzeit: 2016-2030
Projektleiter: PD Dr. Dr. Eva Juengel, Dr. Sascha Markowitsch

Antitumoral effects of sanguinarine on the growth behavior of renal cell carcinoma in vitro

Investigations of the antitumoral efficacy of sanguinarine from Traditional Chinese Medicine (TCM) on the progressive growth of renal cell carcinoma cells. 

Laufzeit: 2023-2027
Projektleiter: PD Dr. Dr. Eva Juengel, Dr. Sascha Markowitsch

Integration of artesunate into a cabozantinib-based therapy concept of renal cell carcinoma in vitro

In the current study we investigate whether artesunate, from Traditional Chinese Medicine (TCM), simultaneously applied with the tyrosine kinase inhibitor (TKI) cabozantinib might induce additive or synergistic antitumor effects in renal cell carcinoma cells.

Laufzeit: 2023-2026
Projektleiter: PD Dr. Dr. Eva Juengel, Prof. Dr. Roman Blaheta

The impact of mistletoe (Iscuin) preparation on cell death induction and associated metabolism in urologic tumor cells

Mistletoe preparations are administered in alternative medicine for various tumor entities. However, the data situation is incomplete. Little is known about effects on urologic tumors. Initial studies showed an antitumor effect of mistletoe preparations on urologic tumor cells. More in-depth analyses should now further investigate the antitumor effects of mistletoe preparations from different host plants on various urologic tumor entities. In particular, the induction of different types of cell death, the formation of reative oxygene species and the influence on cell matabolism after treatment of prostate, bladder and renal cell carcinoma cell lines with different mistletoe extracts will be investigated.

Laufzeit: 2023-2025
Projektleiter: PD Dr. Dr. Eva Jüngel, Dr. Sascha Markowitsch

Preclinical studies to integrate the natural compound sanguinarine into an established first-line treatment for renal cell carcinoma

The planned studies will investigate whether sanguinarine in combination with cabozantinib inhibits the progressive growth behavior of renal cell carcinoma (RCC) in a synergistic or additive manner. Alterations in cell cycle dysregulation and cell death induction as well as modulation of proteins involved will be evaluated. The objective is to determine if and to what extent sanguinarine supports guideline-directed therapy with cabozantinib in RCC cells and to identify the underlying mechanisms. The long-term goal is to provide a more effective treatment option for patients with advanced RCC.

Laufzeit: 2024-2026
Projektleiter: PD Dr. Rene Mager, Dr. Maximilian Brandt, PD Dr. Anita Thomas

Exelixis CL184-313

A Randomized, Double-Blind, Controlled Phase 3 Study of
Cabozantinib in Combination with Nivolumab and Ipilimumab
versus Nivolumab and Ipilimumab in Subjects with Previously
Untreated Advanced or Metastatic Renal Cell Carcinoma of
Intermediate or Poor Risk

Laufzeit: 2020-2025
Projektleiter: PD Dr. Rene Mager, PD Dr. Maximilian Brandt, PD Dr. Anita Thomas

MK3475-564: A Phase III, Randomized, Double-Blind, Placebo-Controlled Clinical Trial of Pembrolizumab (MK-3475) as Monotherapy in the Adjuvant Treatment of Renal Cell Carcinoma Post

Das Ziel dieser klinischen Prüfung ist:
• die Sicherheit und die Verträglichkeit der Prüfmedikation Pembrolizumab (andere Bezeichnung: MK-3475) zu überprüfen;
• die Wirksamkeit von Pembrolizumab im Vergleich mit Placebo (einem identisch aussehenden Präparat ohne Wirkstoff) zu überprüfen.

Laufzeit: 2017-2025
Projektleiter: PD Dr. René Mager

: Impact of primary resistance to front-line targeted therapy in metastatic renal cell carcinoma on subsequent therapy lines in the era of immunotherapy (ReSeq study)

Beschreibung: The objective is to investigate, if primary resistance to 1st line TKI monotherapy predicts response to ICI in subsequent therapy lines and impacts overall survival (OS) in metastatic renal cell carcinoma.

Laufzeit: 2022-2025
Projektleiter: Dr. Stephanie Neuberger

Prospektive Erhebung des Antikörperverlaufs (IgG Anti-Spike-Protein) vor und nach einer Booster-Impfung gegen SARS-Cov-2 an einem uroonkologischen Kollektiv unter Therapie

Einleitung:
Ziel der klinischen Studie ist es an einem Kollektiv mit uroonkologischen Patienten einen Antikörperverlauf darzustellen vor und nach einer Booster-Impfung mit einem Impfstoff gegen SARS-Cov2.
Inhalt:
50 Patienten mit einer uroonkologischen Diagnose (Prostatakarzinom, Urothelkarzinom, Nierenzellkarzinom) und unter palliativer medikamentöser Tumortherapie (Antihormonelle Therapie, Chemotherapie, Immuntherapie, Target Therapy) wird vor der Boosterimpfung, 4-8 Wochen nach der Booster-Impfung und 6 Monate nach der Boosterimpfung 1 Serumröhrchen (7,5ml) im Rahmen der routinemäßigen Blutentnahme abgenommen für die Anitkörperbestimmung (IgG Anti-Spike-Protein). Auch werden folgende Daten erhoben: Persönliche Daten, Diagnose, Therapie, Datum der abgeschlossenen Erstimpfung, Datum der Boosterimpfung, Impfreaktionen, Nebenwirkungen der Tumortherapie.
Ziel:
Evaluation des Antikörperverlaufs und Darstellung möglicher Unterschiede auf das Impfansprechen zwischen den verschiedenen Therapieregimen

Laufzeit: 2022-2025
Projektleiter: Prof. Dr. Annette Schröder

Untreated distal Hypospadias - Natural history of the foreskin

Multicenter Studie 

Laufzeit: 2022-2025
Projektleiter: Dr. Peter Sparwasser

ReTraNUX

retro- versus transperitoneale robotische NUX à klinische Studie aktuell 8 Patienten rekrutiert (Ziel: 42)

Laufzeit: 2022-2026
Projektleiter: PD Dr. Anita Thomas, PD Dr. Robert Dotzauer

A multicenter, randomized, double-blind, placebo-controlled, phase III study of ARN-509 in men with non-metastatic (M0) castration-resistant prostate cancer (SPARTAN)

A multicenter, randomized, double-blind, placebo-controlled, phase III study of ARN-509 in men with non-metastatic (M0) castration-resistant prostate cancer

Laufzeit: 2014-2025
Projektleiter: Dr. Anita Thomas

Biomarker Penis

Prediktive und prognostische Bedeutung der Proteinbiomarker beim Peniskarzinom

Laufzeit: 2020-2026
Projektleiter: Dr. Anita Thomas

Biomarker Prostata Evaluation neuer Biomarker beim Prostatakarzinom

Suche nach neuen empfindlichen Biomarkern für die Optimierung der Diagnostik und Therapie des Prostatakarzinoms in Blut und Urinproben von Patienten mit diagnostiziertem PCA

Laufzeit: 2020-2026
Projektleiter: Dr. Anita Thomas

Problane

Einfluss vom anatomischen Blasenhalserhalt auf funktionelle und onkologische Ergebnisse nach der robotisch-assistierten laparoskopischen radikalen Prostatovesikulektomie (RALP)

Laufzeit: 2020-2027

Publikationen

Blaheta Roman A., Han Jiaoyan, Oppermann Elsie, Bechstein Wolf Otto, Burkhard Katrin, Haferkamp Axel, Rieger Michael A., Malkomes Patrizia
Autoren der Einrichtung: Blaheta Roman A., Haferkamp Axel
Transglutaminase 2 promotes epithelial-to-mesenchymal transition by regulating the expression of matrix metalloproteinase 7 in colorectal cancer cells via the MEK/ERK signaling pathway
BIOCHIMICA ET BIOPHYSICA ACTA-MOLECULAR BASIS OF DISEASE. 2025; 1871 (1): Article
Datensatz in Web of Science®

Brandt Maximilian Peter, Niklas Roelz, Frey Lisa, Porubsky Stefan, Johanna Lisa, Duwe Gregor, Haack Maximilian, Lache Nina, Roehrich Manuel, Haferkamp Axel
Autoren der Einrichtung: Brandt Maximilian Peter, Niklas Roelz, Frey Lisa, Johanna Lisa, Duwe Gregor, Haack Maximilian, Lache Nina, Haferkamp Axel
Weitere Autoren des Fachbereichs: Porubsky Stefan, Roehrich Manuel
EXPRESSION OF FIBROBLAST-ACTIVATING PROTEIN (FAP) AND <SUP>68</SUP>GA-FAPI-PET-CT AS A NOVEL IMAGING MODALITY IN PATIENTS WITH TESTICULAR CANCER
JOURNAL OF UROLOGY. 2025; 213 (5S): Meeting Abstract
Datensatz in Web of Science®

Del Giudice Francesco, Vestri Annarita, Fegatelli Danilo Alunni, Huesch Tanja, Belsey Jonathan, Nair Rajesh, Skinner Eila C., Chung Benjamin I., Pecoraro Martina, Sciarra Alessandro, Franco Giorgio, Pradere Benjamin, Gazzaniga Paola, Magloicca Fabio Massimo, Panebianco Valeria, De Berardinis Ettore
Autoren der Einrichtung: Huesch Tanja
VI-RADS followed by Photodynamic Transurethral Resection of Non-Muscle-Invasive Bladder Cancer vs White-Light Conventional and Second-resection: the 'CUT-<i>less</i>' Randomised Trial Protocol
BJU INTERNATIONAL. 2025; 135 (2): 346-354 Article
Datensatz in Web of Science®

Dinkel Hendrik, Materna Linus, Stelmach Ramona, Zschabitz Stefanie, Neuberger Stephanie, Aydogdu Can D., Casuscelli Jozefina, Egenolf Timo, Silberg Matteo, Steinestel Julie, Strauss Arne, Kirchhoff Florian, Ahrens Marit, Paffenholz Pia, Cathomas Richard, Ozdemir Berna C., Gossler Christopher, Ivanyi Philipp, Rehlinghaus Marc, Hilser Thomas, Grunwald Viktor, Schlack Katrin
Erstautoren: Dinkel Hendrik, Materna Linus
Autoren der Einrichtung: Neuberger Stephanie
Real-world efficacy and toxicity of ipilimumab and nivolumab as a first-line treatment for advanced renal cell carcinoma according to IMDC risk criteria-A multi-center retrospective analysis on behalf of the GUARDIANS group
INTERNATIONAL JOURNAL OF CANCER. 2025: Article
Datensatz in Web of Science®

Doelvers Florian, Pelzer Uwe, Wansch Katharina, Kuehn Anna, Dragomir Mihnea, Bahra Marcus, Felsenstein Matthaeus, Lerchbaumer Markus, Vecchione Loredana, Hilfenhaus Georg, Duwe Gregor, Stint-zing Sebastian, Keilholz Ulrich, Neumann Christopher
Autoren der Einrichtung: Duwe Gregor
Examining differential Tumor Physiology in Primary Tumor and Metastatic Sites in Pancreatic Cancer
INNERE MEDIZIN. 2025; 66: S7-S8 Meeting Abstract
Datensatz in Web of Science®

Duwe Gregor, Mercier Dominique, Kauth Verena, Moench Kerstin, Rajashekar Vikas, Junker Markus, Dengel Andreas, Haferkamp Axel, Hofner Thomas
Autoren der Einrichtung: Duwe Gregor, Kauth Verena, Moench Kerstin, Haferkamp Axel, Hofner Thomas
Development of an artificial intelligence-generated, explainable treatment recommendation system for urothelial carcinoma and renal cell carcinoma to support multidisciplinary cancer conferences
EUROPEAN JOURNAL OF CANCER. 2025; 220: Article
Datensatz in Web of Science®

Duwe Gregor, Mercier Dominique, Kauth Verena, Moench Kerstin, Junker Markus, Dengel Andreas, Haferkamp Axel, Hoefner Thomas
Autoren der Einrichtung: Duwe Gregor, Kauth Verena, Moench Kerstin, Haferkamp Axel
First preliminary results of artificial intelligence-generated, explainable treatment recommendations for renal cell cancer based on multidisciplinary cancer conferences.
JOURNAL OF CLINICAL ONCOLOGY. 2025; 43 (5_SUPPL): Meeting Abstract
Datensatz in Web of Science®

Duwe G., Mercier D., Kauth V., Moench K., Junker M., Dengel A., Haferkamp A., Hofner T.
Autoren der Einrichtung: Duwe G., Kauth V., Moench K., Haferkamp A.
Preliminary results from the KITTU project of artificial intelligence-generated, explainable treatment recommendations for renal cell cancer based on multidisciplinary cancer conferences
EUROPEAN UROLOGY. 2025; 87: Meeting Abstract
Datensatz in Web of Science®

Frey Lisa J., Banasiewicz Katarzyna E., Ruckes Christian, Wagner Isabel, Haack Maximilian, Mager Rene, Juengel Eva, Haferkamp Axel, Duwe Gregor, Brandt Maximilian P.
Autoren der Einrichtung: Frey Lisa J., Banasiewicz Katarzyna E., Wagner Isabel, Haack Maximilian, Mager Rene, Juengel Eva, Haferkamp Axel, Duwe Gregor, Brandt Maximilian P.
Weitere Autoren des Fachbereichs: Ruckes Christian
Complications and oncologic outcome in bladder cancer patients receiving radical cystectomy after intravesical instillation treatment
PLOS ONE. 2025; 20 (12): Article
Datensatz in Web of Science®

Garaz Radion, Mirvald Cristian, Surcel Cristian, Muneer Asif, Thomas Anita, Rausch Steffen, Niyazi Maximilian, Haddad Hathal, Hoffmann Elgin, Vakhrusheva Olesya, Tsaur Igor
Autoren der Einrichtung: Thomas Anita
Evaluating the role of adjuvant therapy in improving outcomes for patients with lymph node-positive penile cancer following surgical management
UROLOGIC ONCOLOGY-SEMINARS AND ORIGINAL INVESTIGATIONS. 2025; 43 (9): 485-497 Review
Datensatz in Web of Science®

Garaz Radion, Erne Eva, Rausch Steffen, Thomas Anita, Surcel Cristian, Mirvald Cristian, Tsaur Igor
Autoren der Einrichtung: Thomas Anita
Systemic treatment in metastatic penile cancer: current landscape, challenges, and future directions
MEMO-MAGAZINE OF EUROPEAN MEDICAL ONCOLOGY. 2025; 18 (3): 163-169 Review
Datensatz in Web of Science®

Giannini Giulia, Kafka Mona, Neuwirt Hannes, Artamonova Nastasiia, di Santo Gianpaolo, Virgolini Irene, Dotzauer Robert, Deiss Emil, Paffenholz Pia, Heidenreich Axel, Rasul Sazan, Tsaur Igor, Rausch Steffen, Einspieler Holger, la Fougere Christian, Trautwein Nils F., Zattoni Fabio, Sepulcri Matteo, Heidegger Isabel
Erstautoren: Giannini Giulia, Kafka Mona
Autoren der Einrichtung: Dotzauer Robert
Safety and Efficacy of 177 Lu-PSMA Therapy Following 223 Radium Treatment: A Retrospective Multinational Real-World Analysis
CLINICAL GENITOURINARY CANCER. 2025; 23 (1): Article
Datensatz in Web of Science®

Haack Maximilian, Turkman Mohamad, Jorg Tobias, Mueller Lukas, Duwe Gregor, Frey Lisa Johanna, Brandt Maximilian Peter, Haferkamp Axel, Borgmann Hendrik, Dotzauer Robert
Autoren der Einrichtung: Haack Maximilian, Turkman Mohamad, Duwe Gregor, Frey Lisa Johanna, Brandt Maximilian Peter, Haferkamp Axel, Dotzauer Robert
Weitere Autoren des Fachbereichs: Jorg Tobias, Mueller Lukas
Impact of the PI-QUAL MRI quality score on histopathological up-staging from MRI fusion biopsy to final prostatectomy specimen
WORLD JOURNAL OF UROLOGY. 2025; 43 (1): Article
Datensatz in Web of Science®

Haack Maximilian, Neuberger Stephanie, Boerner Jan Hendrik, Ziewers Stefanie, Duwe Gregor, Dotzauer Robert, Haferkamp Axel, Mager Rene
Autoren der Einrichtung: Haack Maximilian, Neuberger Stephanie, Boerner Jan Hendrik, Ziewers Stefanie, Duwe Gregor, Dotzauer Robert, Haferkamp Axel, Mager Rene
Real-world comparison of the efficacy of first-line therapies and the influence of risk factors in advanced renal cell carcinoma
DISCOVER ONCOLOGY. 2025; 16 (1): Article
Datensatz in Web of Science®

Haferkamp Axel, Frey Lisa, Duwe Gregor, Borner Jan Hendrik, Hunfeld Carola, Brocker Kerstin A., Troilo Stella, Lehmacher Walter, Papp C. Patrick, Miller Kurt, Wiemer Laura
Autoren der Einrichtung: Haferkamp Axel, Frey Lisa, Duwe Gregor, Borner Jan Hendrik
App-based therapy for female patients with urinary incontinence in Germany (DINKS): a single-blind, randomised, controlled trial
LANCET DIGITAL HEALTH. 2025; 7 (12): Article
Datensatz in Web of Science®

Hoffmann Michele J., Schubert Maria, Erdmann Kati, Schneidewind Laila, Theil Gerit, von Brandenstein Melanie Freifrau, Juengel Eva, Junker Kerstin
Autoren der Einrichtung: Juengel Eva
Women in urological Research: Benefits and Opportunities for German Urology
UROLOGIE. 2025; 64 (8): 825-829 Editorial Material
Datensatz in Web of Science®

Huesch Tanja, Ober Sita, Thomas Anita, Haferkamp Axel, Saar Matthias, Kranz Jennifer
Autoren der Einrichtung: Huesch Tanja, Ober Sita, Thomas Anita, Haferkamp Axel
Reliability of digital health information on stress urinary incontinence compared between different platforms
UROLOGIE. 2025; 64 (6): 567-573 Article
Datensatz in Web of Science®

Jamaer Caroline, De Loof Manon, Van der Jeugt Jolien, Vandamme Ellen, Waterschoot Mieke, Stein Raimund, Peycelon Matthieu, Burgu Berk, Van Laecke Erik, Hoebeke Piet, Spinoit Anne-Francoise
Erstautoren: Jamaer Caroline, De Loof Manon
Autoren der Einrichtung: Stein Raimund
Intravesical Injection of Bulking Agents: Validation of the Ghent University Hospital Porcine Teaching Model
EUROPEAN UROLOGY OPEN SCIENCE. 2025; 78: 1-8 Article
Datensatz in Web of Science®

Kamdem Michael Hermann Kengne, Grein Timothy, Silihe Kevine Kamga, Maxeiner Sebastian, Rutz Jochen, Mmutlane Edwin Mpho, Njamen Dieudonne, Ndinteh Derek Tantoh, Zingue Stephane, Blaheta Roman A.
Seniorautoren: Zingue Stephane, Blaheta Roman A.
Autoren der Einrichtung: Grein Timothy, Maxeiner Sebastian, Rutz Jochen, Blaheta Roman A.
Potential mechanisms by which oleanic and maslinic acids from Cola lateritia K. Schum (Sterculiaceae) twigs inhibit prostate cancer cell growth
SOUTH AFRICAN JOURNAL OF BOTANY. 2025; 181: 52-66 Article
Datensatz in Web of Science®

Kuehn Anna, Pelzer Uwe, Wansch Katharina, Doelvers Florian, Dragomir Mihnea-Paul, Felsenstein Matthaeus, Bahra Marcus, Hilfenhaus Georg, Vecchione Loredana, Lerchbaumer Markus, Duwe Gregor, Stintzing Sebastian, Keilholz Ulrich, Neumann Christopher
Autoren der Einrichtung: Duwe Gregor
Organoid-Based Investigation of Resistance Mechanisms and Derivation of Novel Treatment Options for Cholangiocarcinoma
INNERE MEDIZIN. 2025; 66: S87-S88 Meeting Abstract
Datensatz in Web of Science®

Mager Rene, Tsaur Igor, Hoefner Thomas, Gheith Mohamed Kamal, Duwe Gregor, Haack Maximilian, Azar Jonathan, Aboulmaouahib Brahim, Ziewers Stefanie, Sparwasser Peter, Frey Lisa, Thomas Anita, Haferkamp Axel
Autoren der Einrichtung: Mager Rene, Tsaur Igor, Hoefner Thomas, Gheith Mohamed Kamal, Duwe Gregor, Haack Maximilian, Azar Jonathan, Ziewers Stefanie, Sparwasser Peter, Frey Lisa, Thomas Anita, Haferkamp Axel
Weitere Autoren des Fachbereichs: Aboulmaouahib Brahim
Retroperitoneal Versus Transperitoneal Robot Assisted Partial Nephrectomy: A Prospective Controlled Non-Randomized Single Centre Study Non-Inferiority Design
INTERNATIONAL JOURNAL OF MEDICAL ROBOTICS AND COMPUTER ASSISTED SURGERY. 2025; 21 (3): 7 Article
Datensatz in Web of Science®

Markowitsch Sascha D., Albrecht Larissa, Meiborg Moritz, Rutz Jochen, Thomas Anita, Chun Felix K. -H., Haferkamp Axel, Juengel Eva, Blaheta Roman A.
Seniorautoren: Juengel Eva, Blaheta Roman A.
Autoren der Einrichtung: Markowitsch Sascha D., Albrecht Larissa, Rutz Jochen, Thomas Anita, Haferkamp Axel, Juengel Eva, Blaheta Roman A.
Mistletoe Extracts Inhibit Progressive Growth of Prostate Cancer Cells
CELLS. 2025; 14 (19): Article
Datensatz in Web of Science®

Mercier Dominique, Duwe Gregor, Hofner Thomas, Haferkamp Axel, Dengel Andreas
Autoren der Einrichtung: Duwe Gregor, Hofner Thomas, Haferkamp Axel
Response to letter Re: "Development of an artificial intelligence-generated, explainable treatment recommendation system for urothelial carcinoma and renal cell carcinoma to support multidisciplinary cancer conferences"
EUROPEAN JOURNAL OF CANCER. 2025; 230: Letter
Datensatz in Web of Science®

Reitz Andre, Haferkamp Axel, Gilfrich Christian, Buse Stephan
Autoren der Einrichtung: Haferkamp Axel
Sacral Neurostimulation in Neurogenic Lower Urinary Tract and Bowel Dysfunction Caused by Multiple System Atrophy
NEUROUROLOGY AND URODYNAMICS. 2025; 44 (6): 1296-1301 Article
Datensatz in Web of Science®

Ren Wenbiao, Zhu Yewen
Autoren der Einrichtung: Zhu Yewen
Causal Associations Between the Presence of Prostate Cancer or Testosterone Levels and Bladder Cancer Risk: A Mendelian Randomization Study
CLINICAL GENITOURINARY CANCER. 2025; 23 (3): Article
Datensatz in Web of Science®

Schroeder Annette
Autoren der Einrichtung: Schroeder Annette
Pediatric urology-common issues of the external genitalia in boys
UROLOGIE. 2025; 64 (7): 653-659 Article
Datensatz in Web of Science®

Stelmach Ramona, Zschaebitz Stefanie, Erdmann Stella, Schlack Katrin, Materna Linus, Hilser Thomas, Ivanyi Philipp, Retz Margitta, Casuscelli Jozefina, Paffenholz Pia, Schnabel Marco J., Egenolf Timo, Strauss Arne, Cathomas Richard, Ozdemir Berna C., Moderegger Anton, Neuberger Stephanie, Roghmann Florian, Gruenwald Viktor, Darr Christopher, GUARDIAN Study Grp ?
Autoren der Einrichtung: Neuberger Stephanie
Comparing the effectiveness of IO-based combination regimens as first-line treatment for advanced clear-cell renal cell carcinoma (ccRCC).
JOURNAL OF CLINICAL ONCOLOGY. 2025; 43 (5_SUPPL): Meeting Abstract
Datensatz in Web of Science®

Stenzel P. J., Tagscherer K. E., Justenhoven C., Wild P. J., Haferkamp A., Macher-Goeppinger S., Roth W., Frees S., Porubsky S.
Seniorautoren: Frees S., Porubsky S.
Autoren der Einrichtung: Haferkamp A., Frees S.
Weitere Autoren des Fachbereichs: Stenzel P. J., Tagscherer K. E., Macher-Goeppinger S., Roth W., Porubsky S.
RCC-Ma loss predicts poor survival and metastatic risk in clear cell renal cell carcinoma
PATHOLOGY RESEARCH AND PRACTICE. 2025; 269: Article
Datensatz in Web of Science®

Stenzel P. J., Thomas A., Schindeldecker M., Macher-Goeppinger S., Porubsky S., Haferkamp A., Tsaur I., Roth W., Tagscherer K. E.
Autoren der Einrichtung: Thomas A., Haferkamp A.
Weitere Autoren des Fachbereichs: Stenzel P. J., Schindeldecker M., Macher-Goeppinger S., Porubsky S., Roth W., Tagscherer K. E.
Tumor-infiltrating plasma cells are a prognostic factor in penile squamous cell carcinoma
VIRCHOWS ARCHIV. 2025: Article
Datensatz in Web of Science®

Synoverskyy Pavlo, Hijazi Sameh, Krüer Thomas, Haferkamp Axel, Brandt Maximilian Peter
Autoren der Einrichtung: Synoverskyy Pavlo, Haferkamp Axel, Brandt Maximilian Peter
A Rare Case of Primary Signet Ring Cell Carcinoma of the Urinary Bladder in a Young Woman
Case Reports in Urology. 2025: 4

Thomas Anita, Slade Kimberly Sue, Vakhrusheva Olesya, Kobelt Dennis, Hoffmann Jens, Michaelis Martin, Cintal Jindrich, Rothweiler Florian, Haferkamp Axel, Tsaur Igor
Autoren der Einrichtung: Thomas Anita, Slade Kimberly Sue, Vakhrusheva Olesya, Haferkamp Axel
EVALUATING C-MET INHIBITORS TIVANTINIB AND CABOZANTINIB AS NOVEL THERAPEUTIC OPTIONS IN PENILE CANCER
JOURNAL OF UROLOGY. 2025; 213 (5S): Meeting Abstract
Datensatz in Web of Science®

Thomas Anita, Slade Kimberly Sue, Vakhrusheva Olesya, Michaelis Martin, Cintal Jindrich, Rothweiler Florian, Zhu Yewen, Rajalingam Krishna, Haferkamp Axel, Gaida Matthias, Eckert Christoph, Tsaur Igor
Autoren der Einrichtung: Thomas Anita, Slade Kimberly Sue, Vakhrusheva Olesya, Zhu Yewen, Haferkamp Axel
Weitere Autoren des Fachbereichs: Rajalingam Krishna, Gaida Matthias, Eckert Christoph
TARGETING THE UBIQUITIN-PROTEASOME PATHWAY: NOVEL THERAPEUTIC APPROACHES TO OVERCOME CISPLATIN RESISTANCE IN PENILE CANCER
JOURNAL OF UROLOGY. 2025; 213 (5S): Meeting Abstract
Datensatz in Web of Science®

Tricard Thibault, Comeau Deborah, Lott Celine, Huesch Tanja, Gaillard Victor
Autoren der Einrichtung: Huesch Tanja
The surgeon's assessment of endoscopic image quality is not reliable: A prospective monocentric study
FRENCH JOURNAL OF UROLOGY. 2025; 35 (12): Article
Datensatz in Web of Science®

Vakhrusheva Olesya, Zhao Fuguang, Markowitsch Sascha Dennis, Slade Kimberly Sue, Brandt Maximilian Peter, Tsaur Igor, Cinatl Jr Jindrich, Michaelis Martin, Efferth Thomas, Blaheta Roman Alexander, Haferkamp Axel, Juengel Eva
Erstautoren: Vakhrusheva Olesya, Zhao Fuguang
Autoren der Einrichtung: Vakhrusheva Olesya, Zhao Fuguang, Markowitsch Sascha Dennis, Slade Kimberly Sue, Brandt Maximilian Peter, Tsaur Igor, Blaheta Roman Alexander, Haferkamp Axel, Juengel Eva
Artesunate Inhibits Metastatic Potential in Cisplatin-Resistant Bladder Cancer Cells by Altering Integrins
CELLS. 2025; 14 (8): Article
Datensatz in Web of Science®

Wansch Katharina, Schneider Francois, Dolvers Florian, Kuhn Anna, Dragomir Mihnea P., Joosten Maria, Hilfenhaus Georg, Vecchione Loredana, Felsenstein Matthaus, Lerchbaumer Markus, Jurgensen Christian, Bahra Marcus, Duwe Gregor, Schafer Reinhold, Stintzing Sebastian, Keilholz Ulrich, Neumann Christopher C. M., Pelzer Uwe
Autoren der Einrichtung: Duwe Gregor
Identifying Factors of Organoid Establishment in Pancreatic Cancer: A Prospective Observational Study
CANCER MEDICINE. 2025; 15 (1): Article
Datensatz in Web of Science®

Wansch Katharina, Pelzer Uwe, Doelvers Florian, Kuehn Anna, Dragomir Mihnea-Paul, Felsenstein Matthaues, Bahra Markus, Vecchione Loredana, Hilfenhaus Georg, Lerchbaumer Markus, Duwe Gregor, Stintzing Sebastian, Keilholz Ulrich, Neumann Christopher
Autoren der Einrichtung: Duwe Gregor
Intrinsic and acquired Chemotherapy Resistance in Patient-Derived Organoids of Pancreatic Cancer
INNERE MEDIZIN. 2025; 66: S87-S87 Meeting Abstract
Datensatz in Web of Science®

Wansch Katharina, Pelzer Uwe, Schneider Francois, Dolvers Florian, Kuhn Anna, Dragomir Mihnea P., Ihlow Jana, Hilfenhaus Georg, Vecchione Loredana, Felsenstein Matthaus, Ma Dou, Lerchbaumer Markus, Jurgensen Christian, Bahra Marcus, Granada Adrian E., Duwe Gregor, Stintzing Sebastian, Keilholz Ulrich, Neumann Christopher C. M.
Autoren der Einrichtung: Duwe Gregor
Multi-drug pharmacotyping improves therapy prediction in pancreatic cancer organoids
CANCER CELL INTERNATIONAL. 2025; 25 (1): Article
Datensatz in Web of Science®

Auswahl an wissenschaftlichen Vorträgen

Daniel Beus
Artesunat hemmt den Tumorprogress von Prostatakarzinom-Zellen über verschiedene Integrine.
65. Jahrestagung der Südwestdeutschen Gesellschaft für Urologie e.V.

Daniel Beus
The effects of Artesunate in combination with Cabozantinib in renal cell carcinoma cells.
Transmed Science Day 2025

PD Dr. Maximilian Brandt
Expression therapeutischer Targets beim Urothel- und Plattenepithelkarzinom der Harnblase.
16. Symposium Urologische Forschung der Deutschen Gesellschaft für Urologie

Dr. Gregor Duwe
Automatisierte, erklärbare Therapieempfehlungen für Urothel- und Nierenzellkarzinome mittels Künstlicher Intelligenz zur Unterstützung des urologischen Tumorboards – Ergebnisse und weiterer Ausblick des KITTU Projekts.
65. Jahrestagung der Südwestdeutschen Gesellschaft für Urologie e.V.

Dr. Gregor Duwe
First preliminary results of artificial intelligence-generated, explainable treatment recommendations for renal cell cancer based on multidisciplinary cancer conferences.
American Society of Clinical Oncology Genitourinary Cancer Symposium

Dr. Gregor Duwe
Künstliche Intelligenz-generierte, erklärbare Therapieempfehlungen für Urothel- und Nierenzellkarzinome als Unterstützung für multidisziplinäre Tumorkonferenzen: KI-Entwicklung und erste Ergebnisse aus dem KITTU Projekt.
77. Kongress der Deutschen Gesellschaft für Urologie e.V.

Dr. Gregor Duwe
Preliminary results from the KITTU project of artificial intelligence-generated, explainable treatment recommendations for renal cell cancer based on multidisciplinary cancer conferences.
40th Annual European Association of Urology Congress

Dr. Maximilian Haack
3D Cancer-on-Chip Platform for Modeling Prostate Cancer Bone Metastasis and Evaluating Pharmaceutical Targeting Strategies.
Annual Meeting 2025 of the German Society for Biomaterials (DGBM)

Dr. Maximilian Haack
Up-Staging from MRI Fusion Biopsy to Final Prostatectomy Specimen: Influence of PI-QUAL.
40th Annual European Association of Urology Congress

PD Dr. René Mager
Aktuelle Evidenzlage zum spontanen Steinabgang.
77. Kongress der Deutschen Gesellschaft für Urologie e.V.

PD Dr. René Mager
Was gibt‘s Neues? Game Changer 2024/25 Urothelkarzinom.
65. Jahrestagung der Südwestdeutschen Gesellschaft für Urologie e.V.

Dr. Sascha Markowitsch
Die Integration von Naturstoffen erhöht die Wirksamkeit von Cabozantinib beim Nierenzellkarzinom in vitro.
16. Symposium Urologische Forschung der Deutschen Gesellschaft für Urologie

Dr. Sascha Markowitsch
Naturstoffe aus der Traditionellen Chinesischen Medizin induzieren verschiedene Arten von Zelltoden in Nierenzellkarzinom-Zellen.
65. Jahrestagung der Südwestdeutschen Gesellschaft für Urologie e.V.

Dr. Jochen Rutz
Bedeutung der CD44-HDAC-Interaktion für das Wachstum von Blasentumorzellen in vitro.
65. Jahrestagung der Südwestdeutschen Gesellschaft für Urologie e.V.

Eva-Maria Schorsch
Einfluss des HDAC-Inhibitors Valproat auf das Wachstum und die Motilität von Peniskrebszellen in vitro.
65. Jahrestagung der Südwestdeutschen Gesellschaft für Urologie e.V.

Eva-Maria Schorsch
Immunomodulatory Capacities of Natural Compounds.
Transmed Science Day 2025

Promotionen

Alexandra Sita Ober
Beckenbodeninsuffizienz im Zeitalter der Digitalisierung: Evaluierung von Kontext und Informationsgehalt in digitalen Medien

Johannes Matthias Oetzel
Methodische Bildanalyse von mpMRT-Bildern der Prostata im Rahmen des onkologischen Follow-up von Patienten mit fokaler Therapie des Prostatakarzinoms mittels HIFU Focal One ®

Katja Reisen
Verständnis der Tumorlokalisation in der multiparametrischen MRT der Prostata - Untersuchung der Wirksamkeit von 3D-Druckmodellen

Tim Schykowski
Evaluation von Komplikationen der transperinealen Prostatabiopsie ohne periinterventionelle Antibiotika-Prophylaxe und ohne präinterventionelles Screening für Bakteriurie - eine monozentrische retrospektive klinische Studie

Verschiedene wissenschaftliche Aktivitäten

Preise

Dr. Gregor Duwe
AUA Global Residents Leadership Retreat 2025. American Urological Association (AUA) Annual Meeting, USA. Stipendiat der Deutschen Gesellschaft für Urologie.

Dr. Gregor Duwe
C. E. Alken-Preis für hervorragende wissenschaftliche Leistungen auf dem Gebiet der Urologie. 48. C. E. Alken-Preisträgertreffen 2025, Düsseldorf.

Dr. Gregor Duwe
Forschungs- und Innovationspreis für urologische Onkologie. Deutsche Gesellschaft für Urologie.

Dr. Gregor Duwe
Ideenwettbewerb Rheinland-Pfalz Gewinner „Medizinsonderpreis“ 2025.

Dr. Sascha Markowitsch
Posterpreis. 16. Symposium Urologische Forschung der Deutschen Gesellschaft für Urologie.

Sonstiges

PD Dr. René Mager
Mitglied im Arbeitskreis Harnsteine der Deutschen Gesellschaft für Urologie

PD Dr. René Mager
Reviewer: World Journal of Urology